Research and innovation are at the heart of ALIMA’s work. Our goal is to propose innovative solutions to meet the challenges of humanitarian medicine in the 21st century.

To achieve this, ALIMA’s projects adapt medical research to the context of humanitarian operations.


  • In Africa, 60% of deaths are linked to infectious diseases, most of these deaths are preventable.
  • Only 2.6% of research projects are conducted on the African continent.
  • Current medical research is not adapted to the challenges of humanitarian aid.

ALIMA’s model of research and innovation means we are able to utilize research to provide effective and contextually appropropriate medical care within the regions where we work.


research projects conducted by ALIMA since its creation in 2009

20 %

of ALIMA’s work is devoted to medical research ranging from infectious diseases to the treatment of malnutrition


current research projects with local partners addressing malnutrition, disease prevention and vaccines among others

ALIMA’s Response

CORAL, a collaborative research platform

In 2016, ALIMA and its partners created a unique model of research dedicated to humanitarian medical research, via an alliance between researchers, health workers and NGOs in Africa and Europe.

Thus, ALIMA and the INSERM1219 IDLIC (Infectious Diseases in Lower-Income Countries) team built the CORAL (Clinical and Operational Research Alliance) platform, to combat existing emerging health threats in Africa.

The platform integrates several teams from Inserm (French National Institute of Health and Medical Research) and PAC-CI, a research site based in Ivory Coast, which is part of the French National Agency for Research on AIDS and Hepatitis (ANRS).

The CORAL platform offers innovative solutions to improve the effectiveness of humanitarian medical interventions and relies on Northern-Southern countries partnership, with all projects led by teams from developing countries.

Research for Better Management of Malnutrition

In 2016 and 2018, the OptiMA study (Optimising the Treatment of Malnutrition) demonstrated the ability to improve the care of malnourished children by combining the MUAC strategy (mothers measuring the Mid-Upper Arm Circumference r of children) for early referral of sick children and the simplification of their treatment. ALIMA is also conducting OptiMA study in Niger, Mali and the Democratic Republic of the Congo. Read more

Clinical Research to Better Treat and Prevent Viral Hemorrhagic Fever

Recently, ALIMA has carried out research projects in health emergencies, particularly during outbreaks of viral haemorrhagic fevers.

  • ALIMA implemented the PREVAC project, a vaccine trial comparing the effectiveness of several Ebola vaccine strategies. Read more
  • In Nigeria in 2018, to fight Lassa fever, ALIMA established a partnership with Inserm through the ALERRT consortium (The African coaLition for Epidemic Research, Response and Training) and in coordination with the Nigeria Centre for Disease Control and the World Health Organization. A research team is currently conducting the LASCOPE project, which aims to better understand and describe the disease, while working on the evaluation of therapeutic strategies. Read more
  • In 2019, as part of the response to the Ebola outbreak in the Democratic Republic of the Congo, ALIMA and its research partners participated in a randomized controlled clinical trial comparing experimental treatments for the Ebola Virus. The objective of the trial was to identify the most effective drug among four promising molecules. Two of them were found to be effective in reducing the initial mortality rate from 70% to 30%: Ebola is no longer a fatal disease

ALIMA is currently carrying out 15 innovative research projects to find solutions that transform humanitarian medicine.


* Cover picture © Etinosa Yvonne / ALIMA

© John Wessels / ALIMA


Thank you to our partners !


  • The Ministries of Health in our countries of intervention
  • Inserm – French National Institute of Health and Medical Research
  • PAC-CI – ANRS Program Côte d’Ivoire
  • NIH – United States National Institutes of Health
  • Yale School of Public Health
  • Oxford University
  • ISPED – Institute of Public Health, Epidemiology and Development
  • EDCTP – Europe-Developing Countries Clinical Trials Partnership
  • ALERRT – African Coalition for Training and Response in Epidemic Research
  • ELRHA  
  • The Innocent Foundation 
  • Reacting INSERM
  • The Mitchell Group (TMG) 

Our research Programs



Studying patients to better understand Lassa fever

Clinical trials

Clinical trials

Seeking treatment for Ebola through a randomized clinical trial

CORAL Platform

CORAL Platform

Improving the diagnosis and treatment of infectious diseases


Vaccine trials

Vaccine trials

Setting up vaccine trial programs




Revolutionizing the treatment of highly infectious diseases

Related News

  • Lassa fever in Nigeria: Promising results from a new study will improve the quality of care
    Read more
  • OptiMA research in Burkina Faso: The British Journal of Nutrition publishes promising results from an study
    Read more
  • EBOLA in DRC: Results of the randomized clinical trial published in The New England Journal of Medicine
    Read more
  • Guinea: the results from the study of favipiravir for treatment against ebola prove to be nuanced
    Read more

Get involved with ALIMA !

Help us save more lives by making a donation


Help us save more lives by making a donation


Become a member of ALIMA and take part in our projects

Become a member of ALIMA and take part in major development projects


Join us to transform humanitarian medicine!

Join us if you want to transform humanitarian medicine !


Senegal office

Route de l'Aéroport,
Rue NG 96
BP: 15530. Dakar, Sénégal

France office

15, rue des immeubles industriels 75011 Paris
+33 (0)1 40 33 95 19

USA office

One Whitehall Street, 2nd Fl,
 New York NY 10004
+1 (646) 619-9074

Australia office

15 Hazlewood Street
New Farm, Brisbane
Queensland Australia 4005
 +61 419 744 274
Senegal office
Route de l'Aéroport, Rue NG 96
   BP: 15530. Dakar, Sénégal
France office
15, rue des immeubles industriels
   75011 Paris France.
+33 (0)1 40 33 95 19
USA office
One Whitehall Street, 2nd Fl,
    New York NY 10004, USA
+1 (646) 619-9074
Australia office
PO Box 3716,
  Marsfield NSW 2122, Australia
+61 298682400
For the United States: 100% of your donation will be tax-deductible. ALIMA USA, Inc., is recognized as tax-exempt under section 501(c)(3) of the Internal Revenue Code. EIN: 26-0397519.

For France: Association Law 1901 - Registration and SIREN number : 831 620 398

Under the French tax system, you will benefit from an income tax reduction of 75% of the amount of your donations up to a maximum of 1 000 euros. Beyond that amount, donations are 66% tax deductible up to an equivalent of 20% of your taxable income.